| Similar Articles |
|---|
 |
The Motley Fool
November 3, 2011
Sean Williams |
Bash My Stock: Ariad Pharmaceuticals For those of you who've wondered what's wrong with your stock...   |
The Motley Fool
August 28, 2009
Brian Orelli |
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. |
The Motley Fool
May 6, 2010
Brian Orelli |
Good Deal Now, Bad Deal Later: It's a Biotech Thing Ariad grabs cash now, but gives up long-term sales profits. |
The Motley Fool
December 19, 2011
Brian Orelli |
ARIAD's Prolific 2011 The biotech is doing something right. |
The Motley Fool
August 2, 2007
Andrew R. Vaino |
Ariad Gets Overlooked Ariad Pharmaceuticals has signed a deal with Merck to develop its sarcoma fighting drug. Ariad receives $75 million in cash for R&D, and validation of the drug's worth, but not the attention of investors. |
The Motley Fool
September 27, 2010
Brian Orelli |
Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit. |
The Motley Fool
January 18, 2011
Brian Orelli |
Up 30%, Succeed Indeed! An aptly named clinical trial bodes well for Ariad Pharmaceuticals. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
The Motley Fool
September 24, 2008
Brian Orelli |
Ariad's Lawsuit Loss and Investors' Gamble Ariad Pharmaceuticals announces that it is on the losing end of its lawsuit. |
The Motley Fool
December 9, 2009
Brian Orelli |
Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
October 26, 2010
Travis Hoium |
ARIAD Pharmaceuticals Shares Plunged: What You Need to Know A day after shares pop, the company announced a stock offering at $3.70 per share, and shares drop. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
BusinessWeek
September 5, 2005
Kerry Capell |
Meeting Leukemia's Diagnostic Challenge Tests that distinguish among the disease's many forms either cost too much or don't exist. Dr. Torsten Haferlach And Switzerland's Roche Diagnostics may have a solution. |
The Motley Fool
August 15, 2011
Jim Royal |
6 Wild Bets on Biotech Riches The most interesting biotech tickers. |
The Motley Fool
November 12, 2007
Charly Travers |
The Value of Myriad's Genes Myriad Genetics is unique in the biotech industry because it has a profitable diagnostics business to support its drug research and development efforts, as well as attractive prospects in its pipeline. Investors, take note. |
The Motley Fool
December 31, 2008
Brian Orelli |
Bayer's Little Lost Drug Patent The drugmaker is dusting one off and suing Abbott Labs. |
The Motley Fool
January 27, 2009
Brian Orelli |
Testing a Recession-Resistant Hypothesis Quest Diagnostic looks poised for growth even in bad times. |
Chemistry World
June 12, 2012
Nina Notman |
More testing needed for ridaforolimus US pharma company Merck & Co has confirmed that marketing approval for its anti-cancer drug ridaforolimus has been held up by the US Food and Drug Administration. |
The Motley Fool
June 15, 2011
Selena Maranjian |
Make Money in Biotech the Easy Way There's no need to guess which biotech company will perform best with the SPDR S&P Biotech ETF. |
The Motley Fool
October 19, 2011
Selena Maranjian |
Make Money in Strong Pharma Stocks the Easy Way If you expect the pharmaceutical industry to thrive as our global population grows and ages, the iShares Dow Jones US Pharmaceuticals ETF could save you a lot of trouble. |
